Last reviewed · How we verify
Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of the combination of WX-UK1 and capecitabine in patients with advanced malignancies.
Details
| Lead sponsor | Heidelberg Pharma AG |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 33 |
| Start date | 2004-05 |
Conditions
- Advanced Malignancies
Interventions
- WX-UK1 in combination with Capecitabine
Countries
United States